Keybank National Association OH raised its position in shares of Incyte Corporation (NASDAQ:INCY) by 8.3% during the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,384 shares of the biopharmaceutical company’s stock after buying an additional 644 shares during the quarter. Keybank National Association OH’s holdings in Incyte Corporation were worth $979,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Daiwa Securities Group Inc. raised its stake in Incyte Corporation by 53.4% during the third quarter. Daiwa Securities Group Inc. now owns 30,726 shares of the biopharmaceutical company’s stock valued at $3,587,000 after buying an additional 10,696 shares in the last quarter. Prudential Financial Inc. raised its stake in Incyte Corporation by 0.6% during the third quarter. Prudential Financial Inc. now owns 236,699 shares of the biopharmaceutical company’s stock valued at $27,633,000 after buying an additional 1,490 shares in the last quarter. Cullen Frost Bankers Inc. raised its stake in Incyte Corporation by 7.1% during the third quarter. Cullen Frost Bankers Inc. now owns 51,600 shares of the biopharmaceutical company’s stock valued at $6,024,000 after buying an additional 3,439 shares in the last quarter. State of Wisconsin Investment Board raised its stake in Incyte Corporation by 5.9% during the third quarter. State of Wisconsin Investment Board now owns 252,760 shares of the biopharmaceutical company’s stock valued at $29,507,000 after buying an additional 14,155 shares in the last quarter. Finally, Mn Services Vermogensbeheer B.V. raised its stake in Incyte Corporation by 4.0% during the third quarter. Mn Services Vermogensbeheer B.V. now owns 28,751 shares of the biopharmaceutical company’s stock valued at $3,356,000 after buying an additional 1,100 shares in the last quarter. Hedge funds and other institutional investors own 89.53% of the company’s stock.

INCY has been the topic of several research reports. Raymond James Financial, Inc. upgraded Incyte Corporation from a “market perform” rating to an “outperform” rating and set a $159.00 price objective on the stock in a research note on Monday, September 11th. J P Morgan Chase & Co reiterated a “buy” rating and set a $149.00 price target on shares of Incyte Corporation in a research report on Thursday, August 31st. Oppenheimer Holdings, Inc. reiterated a “hold” rating and set a $135.00 price target on shares of Incyte Corporation in a research report on Thursday, August 31st. BMO Capital Markets reiterated an “outperform” rating and set a $172.00 price target on shares of Incyte Corporation in a research report on Monday, August 28th. Finally, Argus reiterated a “buy” rating and set a $150.00 price target on shares of Incyte Corporation in a research report on Wednesday, September 13th. Seven investment analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. Incyte Corporation currently has an average rating of “Buy” and an average target price of $144.98.

Incyte Corporation (NASDAQ INCY) opened at $105.12 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 4.82 and a quick ratio of 4.81. Incyte Corporation has a one year low of $98.49 and a one year high of $153.15.

Incyte Corporation (NASDAQ:INCY) last issued its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.06 by $0.11. The firm had revenue of $381.50 million during the quarter, compared to analyst estimates of $360.34 million. Incyte Corporation had a negative return on equity of 12.91% and a negative net margin of 10.90%. The firm’s quarterly revenue was up 41.6% on a year-over-year basis. During the same period last year, the company posted $0.19 EPS. research analysts predict that Incyte Corporation will post -1.3 earnings per share for the current fiscal year.

WARNING: “Keybank National Association OH Increases Holdings in Incyte Corporation (INCY)” was originally published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another website, it was copied illegally and republished in violation of international trademark and copyright legislation. The original version of this piece can be viewed at https://www.dailypolitical.com/2017/11/15/keybank-national-association-oh-increases-holdings-in-incyte-corporation-incy.html.

In other news, EVP Steven H. Stein sold 2,111 shares of the stock in a transaction on Tuesday, August 29th. The stock was sold at an average price of $125.00, for a total transaction of $263,875.00. Following the completion of the sale, the executive vice president now owns 18,687 shares in the company, valued at approximately $2,335,875. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider David W. Gryska sold 3,915 shares of the stock in a transaction on Thursday, November 2nd. The shares were sold at an average price of $105.63, for a total value of $413,541.45. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 102,062 shares of company stock valued at $12,652,893. 17.70% of the stock is currently owned by corporate insiders.

Incyte Corporation Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Want to see what other hedge funds are holding INCY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Incyte Corporation (NASDAQ:INCY).

Institutional Ownership by Quarter for Incyte Corporation (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with MarketBeat.com's FREE daily email newsletter.